secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001846253-24-000032
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb Q1 2024 revenue drops to $3.8M; net loss widens to $19.0M
----------------------------------------------------------------

- Revenue $3.8M vs $16.9M YoY; net loss $19.0M ($0.19/share) vs $6.1M ($0.06/share) loss.
- Cash and short-term investments $69.0M; expects 2024 cash use similar to 2023 excluding $35M milestone.
- Signed three new license agreements; 80 active partners, 327 active programs, 31 in clinic.
- Pipeline: batoclimab MG Phase 3 topline H2 2024; IMVT-1402 plans 4-5 registrational programs.
- Guidance: 2024 operating expense flat vs 2023; cash use substantially lower in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000184625324000032/0001846253-24-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000184625324000032/oabi-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001846253-24-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer